Anavex CEO to Present Clinical Prediction Data for ANAVEX 2-73 at CNS Summit 2013

New York, NY — November 7, 2013 — Anavex Life Sciences Corp. (OTCQB: AVXL) is pleased to announce that its President and Chief Executive Officer Christopher U. Missling, PhD, will be presenting new clinical predication data supporting its investigational compound, ANAVEX 2-73, as a potential therapeutic for the treatment of Alzheimer’s disease.  The data will…